United Kingdom: The government of the United Kingdom has announced £4 million in funding for innovative projects to fight Tuberculosis (TB). Ahead of ‘World TB Day,’ UK Development Minister Andrew Mitchell said that Tuberculosis is a devastating disease that could end in our lifetime.
The UN Sustainable Development Goals (SDGs) aim to end this fully preventable and curable disease by 2030, which kills on average 1.3 million people each year, making it the deadliest infectious disease.
TB REACH is funded with £4 million by the UK government to support the development of new strategies that will improve the number of people diagnosed and treated in low- and middle-income countries. As a result of this support, 500,000 people will receive health services, 37,000 cases of Tuberculosis will be detected, and more than 15,000 lives will be saved.
Andrew Mitchell stated that, “TB is a devastating yet eminently preventable disease. The UK has been at the forefront of work to rid the world of it, alongside our partners, and TB REACH will help discover even better ways of detecting and treating the disease, so that people no longer suffer needlessly. It is possible to end TB in our lifetime – we must make every effort to do so.”
TB REACH, which is part of the UK’s Global Fund Accelerator Programme, will be able to finance more institutions with this allowance to try out creative strategies. These approaches will not only aid in bolstering health systems but also in battling antimicrobial resistance.
Over the past several decades, the UK led the fight against TB, and the £1 billion commitment in 2022 to the Global Fund played a crucial role in that fight. It delivers treatment and care for 1.1 million people, screens 20 million people, and offers treatment for multidrug-resistant TB to 41,800 people.
The United Kingdom is a prominent investor in reducing the cost of new products and overcoming obstacles to widespread access to healthcare. To this end, the UK supplies grants to UNITAID, the Clinton Health Access Initiative, and MedAccess.
Analysis of Tuberculosis is crucial and carries the potential to save lives. With its TB Alliance and its Global Alliance for Diagnostics (FIND), the UK plays an important role in developing new drug treatments and diagnostics.
Dr Lucica Ditiu, Executive Director, Stop TB Partnership, remarked that, “TB REACH is the only global mechanism in the TB community that provides fast-track funding directly to implementing partners in country to test innovations. We have supported everything from donkeys to drones, artificial intelligence, portable X-ray and artificial intelligence, new molecular diagnostics, to the vital touch of human TB champions and we look forward to all the new ideas that will be made possible from FCDO’s generous Wave 11 contributions.”
TRENDING | MHRA approves heart disease diagnostic tool
